In addition, when applied in a clinical validation study with 30 lung adenocarcinoma patients harboring epidermal growth factor receptor (EGFR) mutations, the system successfully isolated the full spectrum of CTCs. This evidence concerns the gene EGFR and lung adenocarcinoma.